文献速递痛风与晶体性关节病

别嘌醇与非布司他的超敏反应:基于Medicare理赔数据的研究

Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data.
PubMed 文献 · Ann Rheum Dis · 2020-02-05

该研究利用2006至2012年5% Medicare受益人样本,比较新开具别嘌醇、非布司他或秋水仙碱处方者的超敏反应风险。结果显示,与秋水仙碱相比,别嘌醇和非布司他均显著增加超敏反应风险,但两者之间无显著差异;别嘌醇起始剂量≥300 mg/日、女性及糖尿病与更高风险相关。

要点

  • 与秋水仙碱相比,别嘌醇和非布司他均显著增加超敏反应风险。
  • 倾向匹配分析中,非布司他与别嘌醇的超敏反应风险无显著差异。
  • 别嘌醇起始剂量≥300 mg/日、女性和糖尿病与更高超敏反应风险相关。

核心结论

  • 与秋水仙碱相比,别嘌醇和非布司他均增加超敏反应风险,但两者之间无显著差异。

研究设计与样本

  • 基于2006至2012年5% Medicare受益人(≥65岁)的 population-based 研究,识别新开具别嘌醇、非布司他或秋水仙碱处方者。
  • 采用多变量校正Cox回归比较超敏反应风险比,并进行5:1倾向匹配分析比较别嘌醇与非布司他。

主要发现

  • 超敏反应粗发生率:别嘌醇23.7、非布司他30.7、秋水仙碱25.6每1000人年。
  • 与秋水仙碱相比,别嘌醇、非布司他及非布司他+秋水仙碱的超敏反应HR分别为1.32(95%CI 1.10-1.60)、1.54(95%CI 1.12-2.12)和2.17(95%CI 1.18-3.99)。
  • 倾向匹配分析中,非布司他与别嘌醇的超敏反应HR为1.25(95%CI 0.93-1.67),无显著差异。
  • 与别嘌醇起始剂量<200 mg/日相比,起始剂量≥300 mg/日、糖尿病和女性的超敏反应HR分别为1.27(95%CI 1.12-1.44)、1.21(95%CI 1.00-1.45)和1.32(95%CI 1.17-1.48)。
  • 69%的超敏反应发生在门诊环境。

临床怎么用

  • 处方别嘌醇或非布司他时应监测超敏反应,尤其对于起始剂量≥300 mg/日、女性和糖尿病患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the risk of hypersensitivity reactions (HSRs) with allopurinol and febuxostat in a population-based study. METHODS: We used the 5% Medicare beneficiary sample (≥65 years) from 2006 to 2012 to identify people with a newly filled prescription for allopurinol, febuxostat or colchicine. We used multivariable-adjusted Cox regression analyses to compare the hazard ratio (HR) of incident HSRs with allopurinol or febuxostat use versus colchicine use; separate analyses were done in people exposed to allopurinol. Propensity-matched analyses (5:1) compared hazards with allopurinol versus febuxostat. RESULTS: Crude incidence rates of HSRs were as follows: allopurinol, 23.7; febuxostat, 30.7; and colchicine, 25.6 per 1000 person-years. Compared with colchicine, allopurinol, febuxostat and febuxostat+colchicine were associated with significantly higher HRs of HSRs, 1.32 (95% CI: 1.10 to 1.60) and 1.54 (95% CI: 1.12 to 2.12) and 2.17 (95% CI: 1.18 to 3.99), respectively. In propensity-matched analyses, febuxostat did not significantly differ from allopurinol; HR for HSRs was 1.25 (95% CI: 0.93 to 1.67). Compared with allopurinol start dose <200 mg/day, allopurinol start dose ≥300 mg/day, diabetes and female sex were associated with significantly higher hazard of HSRs, 1.27 (95% CI: 1.12 to 1.44), 1.21 (95% CI: 1.00 to 1.45) and 1.32 (95% CI: 1.17 to 1.48), respectively. The majority (69%) of HSRs occurred in the outpatient setting. CONCLUSIONS: Compared with colchicine, allopurinol and febuxostat similarly increased the risk of HSRs. Allopurinol and febuxostat did not differ from each other. In allopurinol users, starting dose, female sex and diabetes increased this risk, findings that need further study.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Singh JA, Cleveland JD. Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data. Ann Rheum Dis. 2020. PMID: 32024648. doi:10.1136/annrheumdis-2019-216917

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。